Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Lucentis (ranibizumab)
i
Other names:
RG-3645, RG 3645, rhuFabV2, RG3645
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
China Medical System, Novartis, Roche, Santen
Drug class:
VEGF-A inhibitor
Related drugs:
‹
bevacizumab (416)
Aybintio (bevacizumab biosimilar) (14)
bevacizumab-maly (12)
bevacizumab-awwb (11)
bevacizumab-adcd (11)
bevacizumab-tnjn (8)
bevacizumab-bvzr (8)
bevacizumab-nwgd (7)
Byvasda (bevacizumab biosimilar) (4)
ziv-aflibercept IV (4)
BNT327 (2)
SIBP-04 (bevacizumab biosimilar) (1)
CTX-009 (1)
BP102 (bevacizumab biosimilar) (0)
SCT510 (bevacizumab biosimilar) (0)
Ankada (bevacizumab biosimilar) (0)
BI 695502 (bevacizumab biosimilar) (0)
MIL 60 (bevacizumab biosimilar) (0)
LY01008 (bevacizumab biosimilar) (0)
CBT124 (bevacizumab biosimilar) (0)
Cizumab (bevacizumab biosimilar) (0)
Equidacent (bevacizumab biosimilar) (0)
GB222 (bevacizumab biosimilar) (0)
GZ402663 (0)
HLX-04 (bevacizumab biosimilar) (0)
LYN-00101 (0)
MP0250 (0)
MSB0254 (0)
Onbevzi (bevacizumab biosimilar) (0)
PB101 (0)
Pusintin (bevacizumab biosimilar) (0)
TRS003 (bevacizumab biosimilar) (0)
HD204 (bevacizumab biosimilar) (0)
bevacizumab biosimilar (0)
hVEGF26–104/RFASE (0)
APX003 (0)
bevacizumab (416)
Aybintio (bevacizumab biosimilar) (14)
bevacizumab-maly (12)
bevacizumab-awwb (11)
bevacizumab-adcd (11)
bevacizumab-tnjn (8)
bevacizumab-bvzr (8)
bevacizumab-nwgd (7)
Byvasda (bevacizumab biosimilar) (4)
ziv-aflibercept IV (4)
BNT327 (2)
SIBP-04 (bevacizumab biosimilar) (1)
CTX-009 (1)
BP102 (bevacizumab biosimilar) (0)
SCT510 (bevacizumab biosimilar) (0)
Ankada (bevacizumab biosimilar) (0)
BI 695502 (bevacizumab biosimilar) (0)
MIL 60 (bevacizumab biosimilar) (0)
LY01008 (bevacizumab biosimilar) (0)
CBT124 (bevacizumab biosimilar) (0)
Cizumab (bevacizumab biosimilar) (0)
Equidacent (bevacizumab biosimilar) (0)
GB222 (bevacizumab biosimilar) (0)
GZ402663 (0)
HLX-04 (bevacizumab biosimilar) (0)
LYN-00101 (0)
MP0250 (0)
MSB0254 (0)
Onbevzi (bevacizumab biosimilar) (0)
PB101 (0)
Pusintin (bevacizumab biosimilar) (0)
TRS003 (bevacizumab biosimilar) (0)
HD204 (bevacizumab biosimilar) (0)
bevacizumab biosimilar (0)
hVEGF26–104/RFASE (0)
APX003 (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.